The Myelofibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Myelofibrosis Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myelofibrosis Market.

Some of the key takeaways from the Myelofibrosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Myelofibrosis treatment therapies with a considerable amount of success over the years.

• Myelofibrosis companies working in the treatment market are Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others, are developing therapies for the Myelofibrosis treatment

• Emerging Myelofibrosis therapies in the different phases of clinical trials are- LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others are expected to have a significant impact on the Myelofibrosis market in the coming years.

• In March 2026, China’s National Medical Products Administration (NMPA) has granted approval to Sino Biopharmaceutical Ltd.’s rovadicitinib, marketed under the brand name Anxu, for the first-line treatment of adult patients with intermediate- or high-risk primary myelofibrosis, including those with post–polycythemia vera myelofibrosis and post–essential thrombocythemia myelofibrosis.

• In September 2025, Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company specializing in innovative cancer treatments, announced that it has finished enrolling patients in the Phase 3 SENTRY trial. The study is assessing selinexor combined with ruxolitinib in JAK inhibitor–naïve patients with myelofibrosis.

• In November 2024, MorphoSys announced favorable topline results from the Phase III MANIFEST-2 clinical trial evaluating pelabresib for myelofibrosis. The trial assessed pelabresib in combination with Jakafi (ruxolitinib) from Novartis and Incyte, compared to a placebo plus Jakafi, in JAK inhibitor-naïve patients with myelofibrosis.

• In October 2024, Ajax Therapeutics, Inc., a biopharmaceutical company focused on developing next-generation JAK inhibitors for myeloproliferative neoplasms (MPNs), has announced that the first patient has been dosed in its Phase 1 clinical trial of AJ1‑11095, a novel Type II JAK2 inhibitor, for the treatment of myelofibrosis.

Myelofibrosis Overview

Myelofibrosis is a rare type of bone marrow cancer that disrupts the body’s normal production of blood cells. This disease is part of a group of conditions known as myeloproliferative neoplasms. It results in extensive scarring (fibrosis) of the bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen (splenomegaly).

Get a Free Sample PDF Report to know more about Myelofibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight

Emerging Myelofibrosis Drugs Under Different Phases of Clinical Development Include:

• JAKAFI/JAKAVI (ruxolitinib): Incyte/Novartis

• INREBIC (fedratinib): Bristol Myers Squibb

• XPOVIO (selinexor): Karyopharm Therapeutics

• RYTELO (imetelstat): Geron Corporation

• REBLOZYL (luspatercept/ACE-536): Bristol Myers Squibb

• Navtemadlin (KRT-232): Kartos Therapeutics

• Pelabresib (DAK539): Novartis

• Bomedemstat (IMG-7289/MK-3543): Merck

• TL-895: Telios Pharma

• RVU120 ( SEL-120): Ryvu Therapeutics

• TP-3654 (nuvisertib): Syntara

• DISC-0974: Disc Medicine

• ELZONRIS (tagraxofusp/SL-401): Menarini Group

Myelofibrosis Route of Administration

Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

• Molecule Type

Myelofibrosis Molecule Type

Myelofibrosis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

• Product Type

Myelofibrosis Pipeline Therapeutics Assessment

• Myelofibrosis Assessment by Product Type

• Myelofibrosis By Stage and Product Type

• Myelofibrosis Assessment by Route of Administration

• Myelofibrosis By Stage and Route of Administration

• Myelofibrosis Assessment by Molecule Type

• Myelofibrosis by Stage and Molecule Type

DelveInsight’s Myelofibrosis Report covers around 40+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Myelofibrosis product details are provided in the report. Download the Myelofibrosis pipeline report to learn more about the emerging Myelofibrosis therapies

Some of the key companies in the Myelofibrosis Therapeutics Market include:

Key companies developing therapies for Myelofibrosis are – Pharmaxis, Keros Therapeutics, Bristol-Myers Squibb, Ascentage Pharma Group Inc., Sumitomo Pharma Oncology, Galecto Biotech AB, Actuate Therapeutics Inc, Karyopharm Therapeutics Inc, AbbVie, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Taiga Biotechnologies, Inc., Rigel Pharmaceuticals, Celgene, Novartis Pharmaceuticals, Sierra Oncology, Inc., Incyte Corporation, Imago BioSciences, Inc., Samus Therapeutics, Inc., and others.

Myelofibrosis Pipeline Analysis:

The Myelofibrosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.

• Myelofibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myelofibrosis drugs and therapies

Myelofibrosis Pipeline Market Drivers

• Increase in R&D for the development of new and effective drug for the treatment • Increasing Incidence in Elderly Population, development of biological therapies or immunotherapies are some of the important factors that are fueling the Myelofibrosis Market.

Myelofibrosis Pipeline Market Barriers

• However, side effects associated with the drugs, high cost of therapy and other factors are creating obstacles in the Myelofibrosis Market growth.

Scope of Myelofibrosis Pipeline Drug Insight

• Coverage: Global

• Key Myelofibrosis Companies: Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Inc., Keros Therapeutics, Inc., Galecto Biotech AB, Actuate Therapeutics Inc., Karyopharm Therapeutics, AbbVie, Sierra Oncology, and others

• Key Myelofibrosis Therapies: LNK01002, PU-H-71, TBX-2400, BMS-986158, TP-3654, KER-050, GB2064, 9-ING-41, Selinexor, Navitoclax, Momelotinib, and others

• Myelofibrosis Therapeutic Assessment: Myelofibrosis current marketed and Myelofibrosis emerging therapies

• Myelofibrosis Market Dynamics: Myelofibrosis market drivers and Myelofibrosis market barriers

Request for Sample PDF Report for Myelofibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Myelofibrosis Report Introduction

2. Myelofibrosis Executive Summary

3. Myelofibrosis Overview

4. Myelofibrosis- Analytical Perspective In-depth Commercial Assessment

5. Myelofibrosis Pipeline Therapeutics

6. Myelofibrosis Late Stage Products (Phase II/III)

7. Myelofibrosis Mid Stage Products (Phase II)

8. Myelofibrosis Early Stage Products (Phase I)

9. Myelofibrosis Preclinical Stage Products

10. Myelofibrosis Therapeutics Assessment

11. Myelofibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myelofibrosis Key Companies

14. Myelofibrosis Key Products

15. Myelofibrosis Unmet Needs

16 . Myelofibrosis Market Drivers and Barriers

17. Myelofibrosis Future Perspectives and Conclusion

18. Myelofibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/